Larotaxel (CAS 156294-36-9)
Alternate Names:
PNU 100940
CAS Number:
156294-36-9
Molecular Weight:
831.9
Molecular Formula:
C45H53NO14
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data.
QUICK LINKS
Ordering Information
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
Larotaxel, an analog of 10-deacetylbaccatin III, is a semi-synthetic compound known for its antineoplastic properties. The development of larotaxel involved chemical modifications of naturally occurring taxanes to enhance certain properties, such as solubility and the ability to interact with biological molecules. By binding to tubulin, larotaxel facilitates the assembly and stabilization of microtubules, impeding their depolymerization and effectively hindering cell proliferation. Microtubules are structural components within cells that play roles in cell shape, division, and intracellular transport. It effectively halts the rapid proliferation of cancer cells.
Larotaxel (CAS 156294-36-9) References
- Larotaxel: broadening the road with new taxanes. | Metzger-Filho, O., et al. 2009. Expert Opin Investig Drugs. 18: 1183-9. PMID: 19604119
- Isolation and characterization of process-related impurities and degradation products in larotaxel. | Che, X., et al. 2011. J Pharm Biomed Anal. 55: 1190-6. PMID: 21530132
- Eribulin mesylate, a novel microtubule inhibitor in the treatment of breast cancer. | Cortes, J., et al. 2012. Cancer Treat Rev. 38: 143-51. PMID: 21550727
- Development of a UPLC-ESI-MS/MS method for the determination of larotaxel in beagle dog plasma: application to the pharmacokinetic study. | Liu, Z., et al. 2012. Anal Bioanal Chem. 403: 323-30. PMID: 22302171
- Cloud-point extraction combined with HPLC for determination of larotaxel in rat plasma: a pharmacokinetic study of liposome formulation. | Ma, H., et al. 2012. J Sep Sci. 35: 1539-46. PMID: 22707410
- Pharmacokinetics and tissue distribution of larotaxel in rats: comparison of larotaxel-loaded microsphere with larotaxel-solution. | Liu, Z., et al. 2013. Cancer Chemother Pharmacol. 71: 1131-9. PMID: 23412629
- Parenteral formulation of larotaxel lipid microsphere tackling poor solubility and chemical instability. | Teng, F., et al. 2014. Int J Pharm. 460: 212-9. PMID: 24184034
- Determination of larotaxel and its metabolites in rat plasma by liquid chromatography-tandem mass spectrometry: application for a pharmacokinetic study. | Liu, Z., et al. 2014. J Chromatogr B Analyt Technol Biomed Life Sci. 947-948: 132-8. PMID: 24413022
- Synthesis and Cytotoxicity of Two Active Metabolites of Larotaxel. | Li, J., et al. 2016. Anticancer Agents Med Chem. 16: 875-80. PMID: 26830032
- Pharmacokinetics and tissue distribution of larotaxel in rats: comparison of larotaxel solution with larotaxel-loaded folate receptor-targeting amphiphilic copolymer-modified liposomes. | Lu, XF., et al. 2017. Xenobiotica. 47: 416-422. PMID: 27324077
- Characterization of metabolites of larotaxel in rat by liquid chromatography coupled with Q exactive high-resolution benchtop quadrupole orbitrap mass spectrometer. | Liu, Z., et al. 2018. Xenobiotica. 48: 269-278. PMID: 28281396
- Degradation kinetics of larotaxel and identification of its degradation products in alkaline condition. | Liang, X., et al. 2017. J Pharm Anal. 7: 118-122. PMID: 29404026
- Nanostructure of Functional Larotaxel Liposomes Decorated with Guanine-Rich Quadruplex Nucleotide-Lipid Derivative for Treatment of Resistant Breast Cancer. | Li, X., et al. 2021. Small. 17: e2007391. PMID: 33522108
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Larotaxel, 5 mg | sc-488711 | 5 mg | $439.00 |